Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
Monocytes expressing CEA-specific chimeric CD64 receptor target CEA-expressing tumor cells
May 10th, 2006
Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumor cells in vitro and in vivo. According to researchers in England, "Antibody-dependent cellular cytotoxicity (ADCC) is one means by which macrophages (as well as natural killer cells and granulocytes) elicit a cytotoxic response. This is achieved via interaction of the Fc-gamma-receptor (CD64) with the Fc portion of antibody bound to target cells. We have created a chimeric CD64 molecule that incorporates a single chain Fv molecule, targeted against human carcinoembryonic antigen (CEA), fused to the membrane spanning and cytosolic domains of human CD64." ...
Source: Vaccine Weekly (2006-05-10)
|
